UNICA IRIS Institutional Research Information System

SERPE, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 101.999
NA - Nord America 6.833
AS - Asia 2.557
SA - Sud America 407
Continente sconosciuto - Info sul continente non disponibili 206
AF - Africa 64
OC - Oceania 6
AN - Antartide 1
Totale 112.073
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 100.253
US - Stati Uniti d'America 6.735
CN - Cina 1.013
SG - Singapore 912
UA - Ucraina 497
SE - Svezia 375
BR - Brasile 313
DE - Germania 256
VN - Vietnam 224
FI - Finlandia 176
GB - Regno Unito 174
FR - Francia 130
HK - Hong Kong 78
KR - Corea 64
CA - Canada 55
IN - India 55
AR - Argentina 39
BD - Bangladesh 34
TR - Turchia 25
PK - Pakistan 23
RU - Federazione Russa 22
ZA - Sudafrica 21
IQ - Iraq 19
BE - Belgio 18
MX - Messico 17
IR - Iran 16
PL - Polonia 16
ES - Italia 15
ID - Indonesia 15
EC - Ecuador 14
JP - Giappone 14
PH - Filippine 14
KE - Kenya 12
NL - Olanda 11
CO - Colombia 10
MA - Marocco 10
IE - Irlanda 9
AT - Austria 8
SA - Arabia Saudita 8
CH - Svizzera 7
EG - Egitto 7
EU - Europa 7
RS - Serbia 7
VE - Venezuela 7
AU - Australia 6
BG - Bulgaria 6
JM - Giamaica 6
JO - Giordania 6
TN - Tunisia 6
BO - Bolivia 5
CL - Cile 5
CR - Costa Rica 5
PE - Perù 5
UY - Uruguay 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
LT - Lituania 4
PY - Paraguay 4
RO - Romania 4
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
MY - Malesia 3
NI - Nicaragua 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
DZ - Algeria 2
GT - Guatemala 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
PR - Porto Rico 2
TW - Taiwan 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GQ - Guinea Equatoriale 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 111.873
Salva come PNG Salva come JPEG
Città #
Cagliari 98.577
Uta 1.364
Woodbridge 600
Fairfield 577
Ashburn 494
Singapore 452
Dallas 404
Houston 402
Chandler 390
San Jose 322
Ann Arbor 316
Jacksonville 285
Boardman 274
Nyköping 268
Wilmington 251
Seattle 237
Beijing 234
Dearborn 171
Cambridge 170
Los Angeles 100
Helsinki 96
Nanjing 86
Ho Chi Minh City 80
Boston 79
New York 77
Santa Clara 76
Council Bluffs 73
Lauterbourg 73
Hefei 69
Hong Kong 69
Seoul 57
Shanghai 57
The Dalles 49
Hanoi 45
San Diego 45
Buffalo 35
Milan 35
Nanchang 35
Munich 32
Redwood City 32
Guangzhou 29
Changsha 28
Toronto 25
Tianjin 24
São Paulo 23
Hebei 22
Shenyang 22
Jinan 20
London 20
Atlanta 19
Verona 19
Brussels 16
Redondo Beach 16
Norwalk 15
Mountain View 14
Orange 14
Orem 14
Warsaw 14
Zhengzhou 14
Auburn Hills 13
Frankfurt am Main 13
San Francisco 13
Tokyo 13
Baghdad 12
Brooklyn 12
Chennai 12
Phoenix 12
Chicago 11
Nairobi 11
Rome 11
Jiaxing 10
Sassari 10
Waltham 10
Wuhan 9
Augusta 8
Columbus 8
Da Nang 8
Denver 8
Dong Ket 8
Dublin 8
Hangzhou 8
Johannesburg 8
Montreal 8
Rio de Janeiro 8
Shenzhen 8
Thái Nguyên 8
Campinas 7
Haiphong 7
Manchester 7
Naples 7
Nuremberg 7
Nürnberg 7
Pune 7
San Mateo 7
Stockholm 7
Amsterdam 6
Ankara 6
Bielefeld 6
Charlotte 6
Curitiba 6
Totale 107.817
Salva come PNG Salva come JPEG
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.982
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.734
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.436
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.351
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 3.304
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 3.160
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.769
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.703
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.701
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.550
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.437
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.370
null 2.211
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.201
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.194
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 2.093
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 2.087
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 2.080
null 1.987
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.892
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.784
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.733
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.726
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.720
null 1.699
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.693
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.675
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.670
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.593
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.524
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.516
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.484
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.472
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.371
null 1.362
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.330
null 1.063
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 849
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 819
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 803
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 794
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 789
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 788
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 783
null 768
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 743
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 741
Current medications for cancer cachexia 740
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 739
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 732
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 728
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 719
null 709
null 694
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 691
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 683
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 667
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 661
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 588
null 572
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 571
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 566
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 560
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 543
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 536
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 529
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 525
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 505
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 503
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 497
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 497
null 465
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 463
An innovative approach to CACS 461
null 450
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 423
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 419
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 415
null 413
null 390
null 342
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 338
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 333
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 323
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 317
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 309
null 304
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 274
null 267
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 253
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 217
Prognostic role of lipid profile in patients with advanced cancer 212
null 208
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 208
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 160
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 157
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 148
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 147
null 147
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 140
Totale 111.992
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.858
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.861 0 314 179 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20246.816 445 336 335 511 693 1.312 839 473 311 467 584 510
2024/20258.457 1.040 1.647 1.329 1.267 700 1.116 564 104 185 126 184 195
2025/20264.855 300 238 677 435 347 310 717 219 358 640 266 348
2026/2027290 58 232 0 0 0 0 0 0 0 0 0 0
Totale 112.073